XML 50 R34.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Reconciled Consolidated Net Loss
Segment revenue and significant segment expenses which are regularly reported to the CODM are included within the table below and are reconciled to consolidated net loss:
Year ended December 31,
202520242023
Revenue:
Product revenue, net$5,420 $— $— 
Collaboration and license revenue2,276 1,039 4,013 
Total revenue, net7,696 1,039 4,013 
Less:
Cost of product revenue(1,076)— — 
Research and development expenses
Paltusotine(68,337)(51,229)(46,772)
Atumelnant(48,131)(24,524)(13,118)
Other research and development programs(33,322)(26,010)(20,421)
Research and development personnel expenses(102,677)(70,772)(53,446)
Research and development stock-based compensation(50,344)(40,667)(22,633)
Other research and development (1)(29,247)(26,954)(12,137)
Total research and development expenses(332,058)(240,156)(168,527)
Selling, general and administrative
External selling, general and administrative expenses(90,013)(38,733)(20,362)
Selling, general and administrative personnel expenses(60,638)(32,285)(19,428)
Selling, general and administrative stock-based compensation(40,680)(28,719)(18,304)
Total selling, general and administrative expenses(191,331)(99,737)(58,094)
Total other income, net51,632 40,916 13,277 
Income tax expense(180)— — 
Loss on equity method investment— (470)(5,198)
Segment and consolidated net loss$(465,317)$(298,408)$(214,529)
(1)Other research and development is comprised of non-personnel related research and development indirect costs incurred for the benefit of multiple research and development programs, including depreciation, and other facility-based expenses, such as rent expense.